TWD 38.75
(-1.77%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 210.93 Million TWD | -10.48% |
2022 | 235.61 Million TWD | 20.66% |
2021 | 195.26 Million TWD | 57.05% |
2020 | 124.33 Million TWD | -26.03% |
2019 | 168.09 Million TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 319.34 Million TWD | 3.51% |
2024 Q3 | 219.12 Million TWD | -31.38% |
2024 Q1 | 308.51 Million TWD | 46.26% |
2023 Q4 | 210.93 Million TWD | -0.15% |
2023 Q3 | 211.25 Million TWD | -23.57% |
2023 Q2 | 276.38 Million TWD | 6.92% |
2023 Q1 | 258.5 Million TWD | 9.72% |
2022 FY | 235.61 Million TWD | 20.66% |
2022 Q4 | 235.61 Million TWD | 0.0% |
2021 FY | 195.26 Million TWD | 57.05% |
2020 FY | 124.33 Million TWD | -26.03% |
2019 FY | 168.09 Million TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
BIONET Corp. | 626.46 Million TWD | 66.33% |
Genetics Generation Advancement Corp. | 164.9 Million TWD | -27.909% |
Welgene Biotech Co.,Ltd. | 247.89 Million TWD | 14.911% |
Puriblood Medical Co., Ltd. | 84.35 Million TWD | -150.063% |
TFBS Bioscience Inc. | 187.43 Million TWD | -12.535% |